-
2025-523975-48-00
5
2026-05-08
Obesity
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-523557-33-00
4
2026-04-20
Moderate-to-Severe Hidradenitis Suppurativa
-
2025-521456-35-00
4
2026-04-13
Mild to moderate asthma
-
2025-523342-27-00
4
2026-04-10
Alopecia areata
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2025-523347-35-00
11
2026-03-05
Atopic Dermatitis
-
2025-522514-23-00
5
2026-02-12
Urinary Incontinence
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-520831-18-00
4
2025-12-12
Primary Sjogren’s Disease
-
2025-521215-39-00
5
2025-12-08
Schizophrenia
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2023-510026-32-00
5
2025-06-11
Generalized Myasthenia Gravis
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)